Vera Therapeutics reports positive 96-week ORIGIN Phase 2b data for atacicept in IgAN; cash ~$353M

Vera Therapeutics, Inc.

Atacicept showed -66% Gd-IgA1 reduction, 75% hematuria resolution, -52% proteinuria reduction over 96 weeks.
Mean annualized eGFR slope of -0.6 mL/min/1.73m2/year; 90% treatment completion rate.
Phase 3 ORIGIN 3 topline expected Q2 2025; BLA submission planned H2 2025; commercial launch target 2026.
Preliminary unaudited cash, cash equivalents and marketable securities ~$353.2M as of Sep 30, 2024.
Data simultaneously published in Journal of the American Society of Nephrology; presented at ASN Kidney Week.

item 2.02 item 7.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-24-245704
form_type: 8-K
ticker: VERA
cik: 0001831828
company_name: Vera Therapeutics, Inc.
filed_at: 2024-10-28T23:59:59+00:00
discovered_at: 2026-05-14T18:03:09.904752+00:00
generated_at: 2026-05-30T09:47:47.463341+00:00
sec_items: ["2.02", "7.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-24-245704
json_url: https://secwatch.observer/filing/0001193125-24-245704.json
markdown_url: https://secwatch.observer/filing/0001193125-24-245704.md
text_url: https://secwatch.observer/filing/0001193125-24-245704.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312524245704/0001193125-24-245704-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1831828/000119312524245704/d891191d8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Comparable filings

QMCO

Quantum raises $100M equity, converts all convertible notes to equity; Q4 revenue above guidance

QUANTUM CORP /DE/ June 2, 2026, 10:41 AM ET other_material Items 1.01, 2.02, 2.03, 3.02, 8.01, 9.01

same SEC item: 2.02, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CELC

Gedatolisib doubles PFS vs alpelisib in PIK3CA mutant HR+/HER2- ABC Phase 3 trial

Celcuity Inc. June 2, 2026, 8:10 AM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

CSR

Centerspace approves $240-245M asset sales; exits Bismarck and Rapid City

CENTERSPACE June 1, 2026, 4:30 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

IDYA

IDEAYA's darovasertib combo meets primary endpoint in Phase 2/3 OptimUM-02 trial for metastatic uveal melanoma

IDEAYA Biosciences, Inc. June 1, 2026, 4:05 PM ET other_material Items 7.01, 8.01, 9.01

same SEC item: 7.01, 8.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

USAR

USA Rare Earth selects South Carolina for $1.2B magnet facility; 490 jobs, 6,400 tpa capacity

USA Rare Earth, Inc. June 2, 2026, 9:14 AM ET other_material Items 1.01, 2.03, 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

SHAK

Shake Shack cuts Q2 revenue guidance to $415-420M, same-shack sales to 2.5-3.0%

Shake Shack Inc. June 2, 2026, 8:06 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

RZLT

Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint

Rezolute, Inc. June 2, 2026, 7:05 AM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

AII

American Integrity fully places 2026-2027 CAT XOL reinsurance with $2.99B total limit

American Integrity Insurance Group, Inc. June 1, 2026, 4:31 PM ET other_material Items 7.01, 9.01

same SEC item: 7.01, 9.01 same event type: other_material similar materiality

Filing page SEC filing

Source: SEC EDGAR

accession 0001193125-24-245704

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.